Start:
July 1, 2018
End:
May 2025
Enrollment:
160
DHA is an omega-3 fatty acid found in cell membranes throughout the body, particularly in the brain, and helps to transmit messages between nerves. This study will explore whether DHA supplements can increase the amounts of DHA in the brain. In addition, the study will explore if carrying the APOE 4 allele, the strongest genetic risk factor for developing Alzheimer's disease, affects the levels or absorption of DHA in the brain. Participants will be randomly assigned to take a supplement of DHA or placebo once a day for two years. After six months, researchers will measure the amount of DHA in participants spinal fluid. After two years, participants will complete cognition tests and receive an MRI brain scan to help researchers assess the effect of DHA supplementation on changes in brain structure and function.
Minimum Age: 60 Years
Maximum Age: 80 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: University of Southern California
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT03613844
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health